구조모아 (StructureMoa)항암 chemical structure spider web
방문프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | tirzepatide (Mounjaro / Zepbound, Mounjaro, Zepbound, LY3298176) Eli Lilly·GLP-1 / GIP receptor 269 trials·t½ 5 h | semaglutide (Ozempic / Wegovy, GLP-1, Wegovy, NN9535) Novo Nordisk·GLP-1 receptor 410 trials·t½ 168 days |
|---|---|---|
Overview Program | Mounjaro / Zepbound (tirzepatide) | Ozempic / Wegovy (semaglutide) |
Overview Company | Eli Lilly | Novo Nordisk |
Overview Modality | ANTIBODY | ANTIBODY |
Overview Target | GLP-1 / GIP receptor | GLP-1 receptor |
Overview Indication | Type 2 diabetes, chronic weight management | Type 2 diabetes, chronic weight management, CV risk reduction (T2D) |
Overview Phase | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED |
Overview Content status | Curated Core | Curated Core |
Overview Data Confidence | Data Confidence · High | Data Confidence · High |
Overview Development Signal | Development Signal · Established | Development Signal · Established |
Overview Approval status | FDA approved | FDA approved |
Positioning Key differentiator | Dual incretin mechanism vs GLP-1-only agonists | Weekly SC (Ozempic/Wegovy) and oral form (Rybelsus) |
Positioning Known limitation | GI side effects during titration; individualized dose escalation required. | GI intolerance leading to discontinuation; plateau after dose titration |
Positioning Development positioning | — | GLP-1 class anchor vs tirzepatide dual agonist |
MoA Mechanism | Tirzepatide is a 39-amino-acid peptide activating both GIP and GLP-1 receptors, enhancing insulin secretion, reducing glucagon, slowing gastric emptying, and promoting weight loss via combined incretin effects. | Semaglutide activates GLP-1 receptors on pancreatic beta cells (glucose-dependent insulin secretion), suppresses glucagon, slows gastric emptying, and reduces appetite via central pathways. |
MoA Biomarker | HbA1c, body weight, lipids. | HbA1c, body weight, SELECT CV outcomes in obesity with CVD. |
PK/PD Half-life | 5 h | 168 days |
PK/PD Species | Mouse, HbA1c ↓2.0%+ | Rat, HbA1c ↓1.5–1.8%, weight ↓~15% at 68 wk (STEP-1) |
PK/PD Animal (cat.) | Mouse | Rat |
PK/PD Experiment | pharmacokinetic | PK |
Toxicology Species | Mouse, Rat | NHP, Mouse, Rat |
Toxicology Animal (cat.) | — | NHP |
Toxicology Major finding | GI events (nausea, diarrhea) most common; gallbladder disease; thyroid C-cell rodent findings. | Thyroid C-cell tumors in rodents (class warning); GI AEs in clinic |
Toxicology CRS | N/A | N/A |
Clinical Safety signal | GI events (nausea, diarrhea) most common; gallbladder disease; thyroid C-cell rodent findings. | Thyroid C-cell tumors in rodents (class warning); GI AEs in clinic |
Clinical Selected reported efficacy | — | Weight 1.01% |
Clinical Weight % | — | weight loss is essential but difficult |
Clinical Result source | — | ClinicalTrials.gov NCT03480022 |
Clinical Program phase | APPROVED | APPROVED |
Clinical Trial activity | No active/completed counts | No active/completed counts |
Clinical Trial ref | — | NCT03480022 |
Preclinical Animal (cat.) | Mouse | Mouse |
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | tirzepatide (Mounjaro / Zepbound, Mounjaro, Zepbound, LY3298176) Eli Lilly·GLP-1 / GIP receptor 269 trials·t½ 5 h | semaglutide (Ozempic / Wegovy, GLP-1, Wegovy, NN9535) Novo Nordisk·GLP-1 receptor 410 trials·t½ 168 days |
|---|---|---|
Overview Program | Mounjaro / Zepbound (tirzepatide) | Ozempic / Wegovy (semaglutide) |
Overview Company | Eli Lilly | Novo Nordisk |
Overview Modality | ANTIBODY | ANTIBODY |
Overview Target | GLP-1 / GIP receptor | GLP-1 receptor |
Overview Indication | Type 2 diabetes, chronic weight management | Type 2 diabetes, chronic weight management, CV risk reduction (T2D) |
Overview Phase | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED |
Overview Content status | Curated Core | Curated Core |
Overview Data Confidence | Data Confidence · High | Data Confidence · High |
Overview Development Signal | Development Signal · Established | Development Signal · Established |
Overview Approval status | FDA approved | FDA approved |
Positioning Key differentiator | Dual incretin mechanism vs GLP-1-only agonists | Weekly SC (Ozempic/Wegovy) and oral form (Rybelsus) |
Positioning Known limitation | GI side effects during titration; individualized dose escalation required. | GI intolerance leading to discontinuation; plateau after dose titration |
Positioning Development positioning | — | GLP-1 class anchor vs tirzepatide dual agonist |
MoA Mechanism | Tirzepatide is a 39-amino-acid peptide activating both GIP and GLP-1 receptors, enhancing insulin secretion, reducing glucagon, slowing gastric emptying, and promoting weight loss via combined incretin effects. | Semaglutide activates GLP-1 receptors on pancreatic beta cells (glucose-dependent insulin secretion), suppresses glucagon, slows gastric emptying, and reduces appetite via central pathways. |
MoA Biomarker | HbA1c, body weight, lipids. | HbA1c, body weight, SELECT CV outcomes in obesity with CVD. |
PK/PD Half-life | 5 h | 168 days |
PK/PD Species | Mouse, HbA1c ↓2.0%+ | Rat, HbA1c ↓1.5–1.8%, weight ↓~15% at 68 wk (STEP-1) |
PK/PD Animal (cat.) | Mouse | Rat |
PK/PD Experiment | pharmacokinetic | PK |
Toxicology Species | Mouse, Rat | NHP, Mouse, Rat |
Toxicology Animal (cat.) | — | NHP |
Toxicology Major finding | GI events (nausea, diarrhea) most common; gallbladder disease; thyroid C-cell rodent findings. | Thyroid C-cell tumors in rodents (class warning); GI AEs in clinic |
Toxicology CRS | N/A | N/A |
Clinical Safety signal | GI events (nausea, diarrhea) most common; gallbladder disease; thyroid C-cell rodent findings. | Thyroid C-cell tumors in rodents (class warning); GI AEs in clinic |
Clinical Selected reported efficacy | — | Weight 1.01% |
Clinical Weight % | — | weight loss is essential but difficult |
Clinical Result source | — | ClinicalTrials.gov NCT03480022 |
Clinical Program phase | APPROVED | APPROVED |
Clinical Trial activity | No active/completed counts | No active/completed counts |
Clinical Trial ref | — | NCT03480022 |
Preclinical Animal (cat.) | Mouse | Mouse |
추천 비교
추천 비교